The role of IL-4 and IL-13 in cutaneous leishmaniasis

Immunology Letters

Volumn 161, Issue 2, 2014, Pages 179-183

  Hurdayal, Ramona ^a   Brombacher, Frank ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Cutaneous Leishmaniasis; Gene deficient mouse models; IL 13; IL 4; IL 4R

Indexed keywords

INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR ALPHA;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CYTOKINE PRODUCTION; IMMUNOREGULATION; MACROPHAGE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SKIN LEISHMANIASIS; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; ANIMAL; DISEASE COURSE; DISEASE MODEL; GENETICS; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; MOUSE;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; INTERLEUKIN-13; INTERLEUKIN-4; LEISHMANIASIS, CUTANEOUS; MICE; MICE, KNOCKOUT; TH1 CELLS; TH2 CELLS;

EID: 84906790590     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2013.12.022     Document Type: Article

References (32)

1. Kopf M., Brombacher F., Kohler G., Kienzle G., Widmann K.H., Lefrang K., Humborg C., Ledermann B., Solbach W. IL-4-deficient Balb/c mice resist infection with Leishmania major. J Exp Med 1996, 184(3):1127-1136.
2. Matthews D.J., Emson C.L., McKenzie G.J., Jolin H.E., Blackwell J.M., McKenzie A.N. IL-13 is a susceptibility factor for Leishmania major infection. J Immunol 2000, 164(3):1458-1462.
3. Mohrs M., Ledermann B., Kohler G., Dorfmuller A., Gessner A., Brombacher F. Differences between IL-4- and IL-4 receptor alpha-deficient mice in chronic leishmaniasis reveal a protective role for IL-13 receptor signaling. J Immunol 1999, 162(12):7302-7308.
4. Radwanska M., Cutler A.J., Hoving J.C., Magez S., Holscher C., Bohms A., Arendse B., Kirsch R., Hunig T., Alexander J., et al. Deletion of IL-4Ralpha on CD4 T cells renders BALB/c mice resistant to Leishmania major infection. PLoS Pathog 2007, 3(5):pe68.
5. Biedermann T., Zimmermann S., Himmelrich H., Gumy A., Egeter O., Sakrauski A.K., Seegmuller I., Voigt H., Launois P., Levine A.D., et al. IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice. Nat Immunol 2001, 2(11):1054-1060.
6. Noben-Trauth N., Paul W.E., Sacks D.L. IL-4- and IL-4 receptor-deficient BALB/c mice reveal differences in susceptibility to Leishmania major parasite substrains. J Immunol 1999, 162(10):6132-6140.
7. Hurdayal R., Nieuwenhuizen N.E., Revaz-Breton M., Smith L., Hoving J.C., Parihar S.P., Reizis B., Brombacher F. Deletion of IL-4 Receptor Alpha on Dendritic Cells Renders BALB/c Mice Hypersusceptible to Leishmania major Infection. PLoS Pathog 2013, 9(10):e1003699.
8. Alexander J., Carter K.C., Al-Fasi N., Satoskar A., Brombacher F. Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Eur J Immunol 2000, 30(10):2935-2943.
9. McFarlane E., Carter K.C., McKenzie A.N., Kaye P.M., Brombacher F., Alexander J. Endogenous IL-13 plays a crucial role in liver granuloma maturation during Leishmania donovani infection, independent of IL-4Ralpha-responsive macrophages and neutrophils. J Infect Dis 2011, 204(1):36-43.
10. Murray H.W., Tsai C.W., Liu J., Ma X. Visceral Leishmania donovani infection in interleukin-13-/- mice. Infect Immun 2006, 74(4):2487-2490.
11. Stamm L.M., Raisanen-Sokolowski A., Okano M., Russell M.E., David J.R., Satoskar A.R. Mice with STAT6-targeted gene disruption develop a Th1 response and control cutaneous leishmaniasis. J Immunol 1998, 161(11):6180-6188.
12. Noben-Trauth N., Kropf P., Muller I. Susceptibility to Leishmania major infection in interleukin-4-deficient mice. Science 1996, 271(5251):987-990.
13. Satoskar A., Bluethmann H., Alexander J. Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection. Infect Immun 1995, 63(12):4894-4899.
14. Alexander J., Brombacher F., McGachy H.A., McKenzie A.N., Walker W., Carter K.C. An essential role for IL-13 in maintaining a non-healing response following Leishmania mexicana infection. Eur J Immunol 2002, 32(10):2923-2933.
15. Holscher C., Arendse B., Schwegmann A., Myburgh E., Brombacher F. Impairment of alternative macrophage activation delays cutaneous leishmaniasis in nonhealing BALB/c mice. J Immunol 2006, 176(2):1115-1121.
16. Bryson K.J., Millington O.R., Mokgethi T., McGachy H.A., Brombacher F., Alexander J. BALB/c mice deficient in CD4 T cell IL-4Ralpha expression control Leishmania mexicana Load although female but not male mice develop a healer phenotype. PLoS Negl Trop Dis 2011, 5(1):e930.
17. McKenzie G.J., Emson C.L., Bell S.E., Anderson S., Fallon P., Zurawski G., Murray R., Grencis R., McKenzie A.N. Impaired development of Th2 cells in IL-13-deficient mice. Immunity 1998, 9(3):423-432.
18. Satoskar A., Brombacher F., Dai W.J., McInnes I., Liew F.Y., Alexander J., Walker W. SCID mice reconstituted with IL-4-deficient lymphocytes, but not immunocompetent lymphocytes, are resistant to cutaneous leishmaniasis. J Immunol 1997, 159(10):5005-5013.
19. Mohrs M., Holscher C., Brombacher F. Interleukin-4 receptor alpha-deficient BALB/c mice show an unimpaired T helper 2 polarization in response to Leishmania major infection. Infect Immun 2000, 68(4):1773-1780.
20. Kropf P., Schopf L.R., Chung C.L., Xu D., Liew F.Y., Sypek J.P., Muller I. Expression of Th2 cytokines and the stable Th2 marker ST2L in the absence of IL-4 during Leishmania major infection. Eur J Immunol 1999, 29(11):3621-3628.
21. Noben-Trauth N., Shultz L.D., Brombacher F., Urban J.F., Gu H., Paul W.E. An interleukin 4 (IL-4)-independent pathway for CD4+ T cell IL-4 production is revealed in IL-4 receptor-deficient mice. Proc Natl Acad Sci USA 1997, 94(20):10838-10843.
22. Alexander J., Brombacher F. T helper1/t helper2 cells and resistance/susceptibility to leishmania infection: is this paradigm still relevant?. Front Immunol 2012, 3:80.
23. Scott P., Natovitz P., Coffman R.L., Pearce E., Sher A. Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J Exp Med 1988, 168(5):1675-1684.
24. Holscher C., Mohrs M., Dai W.J., Kohler G., Ryffel B., Schaub G.A., Mossmann H., Brombacher F. Tumor necrosis factor alpha-mediated toxic shock in Trypanosoma cruzi-infected interleukin 10-deficient mice. Infect Immun 2000, 68(7):4075-4083.
25. Herbert D.R., Holscher C., Mohrs M., Arendse B., Schwegmann A., Radwanska M., Leeto M., Kirsch R., Hall P., Mossmann H., et al. Alternative macrophage activation is essential for survival during schistosomiasis and downmodulates T helper 1 responses and immunopathology. Immunity 2004, 20(5):623-635.
26. Hochrein H., O'Keeffe M., Luft T., Vandenabeele S., Grumont R.J., Maraskovsky E., Shortman K. Interleukin (IL)-4 is a major regulatory cytokine governing bioactive IL-12 production by mouse and human dendritic cells. J Exp Med 2000, 192(6):823-833.
27. Lutz M.B., Schnare M., Menges M., Rossner S., Rollinghoff M., Schuler G., Gessner A. Differential functions of IL-4 receptor types I and II for dendritic cell maturation and IL-12 production and their dependency on GM-CSF. J Immunol 2002, 169(7):3574-3580.
28. Yao Y., Li W., Kaplan M.H., Chang C.H. Interleukin (IL)-4 inhibits IL-10 to promote IL-12 production by dendritic cells. J Exp Med 2005, 201(12):1899-1903.
29. Masic A., Hurdayal R., Nieuwenhuizen N.E., Brombacher F., Moll H. Dendritic cell-mediated vaccination relies on interleukin-4 receptor signaling to avoid tissue damage after leishmania major infection of BALB/c mice. PLoS Negl Trop Dis 2012, 6(7):e1721.
30. Mazumdar T., Anam K., Ali N. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice. Vaccine 2004, 22(9-10):1162-1171.
31. Gicheru M.M., Olobo J.O., Anjili C.O., Orago A.S., Modabber F., Scott P. Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection. Infect Immun 2001, 69(1):245-251.
32. Kenney R.T., Sacks D.L., Sypek J.P., Vilela L., Gam A.A., Evans-Davis K. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J Immunol 1999, 163(8):4481-4488.